Region

Introducing

Phenomenex bioZen LC Columns

for Biologics Analysis

Phenomenex bioZen Information


  • Explore a New State of Zen for:
  • Peptide Mapping Aggregate Analysis Glycan Analysis Peptide Quantitation Drug Antibody Ratio Intact Mass Intact and Fragment Analysis
 
Ti Biocompatible Titanium Frit
 
Traditional Stainless Steel
 
Ti Biocompatible Titanium

Introducing Phenomenex Biozen HPLC/UHPLC Columns

With a new titanium hardware to minimize priming, four particle platforms for optimal versatility and nine particle chemistries to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns are seamlessly designed to bring peace of mind to your

  • Aggregate Analysis

    Quantitation of aggregate is a critical quality attribute in biopharmaceutical development. The determination of monomer, dimer, and multimer, as well as higher order structure (quaternary structural determination of a mAb), and high/low molecular weight species are commonly observed through size exclusion chromatography.

  • Drug Antibody Ratio (DAR)

    The average drug-to-antibody ratio (DAR) is critical to assess in the development of antibody-drug conjugates (ADCs). Though different chromatography modes can be employed to determine DAR, a highly effective method utilized reversed phase chromatography.

  • Glycan Analysis

    Glycosylation of proteins-specifically monoclonal antibodies-have indications on protein structure and is arguably the most critical post-translational modification to characterize in biopharmaceutical development. N-glycan analysis through hydrophilic interaction chromatography (HILIC) is a robust method for absolute quantitation of glycoforms and is the gold standard for glycosylation characterization.

  • Intact Mass

    Intact mass analysis involves using high resolution accurate mass (HRAM) instrumentation to confirm protein sequence and identify post-translational modifications. Often in combination with reversed phase chromatography, intact mass analysis is utilized on native proteins, mAbs, and ADCs in biopharmaceutical development.

  • Intact and Fragment Analysis

    Observation of intact protein and fragmented protein during impurity profiling is essential in biologic development. Utilizing reversed phase chromatography on native protein and partially fragmented protein scientists can observe characteristics including heavy chain/light chain, Fc/Fab, or isoforms.

  • Peptide Mapping

    For protein characterization, peptide mapping is commonly used for identification of non-enzymatic, spontaneous post translational modifications, such as deamidation, oxidation, succinimide formation, pyroglutamate formation, and others. Reversed phase chromatography is used for confirming primary sequence, but is more commonly for PTM identification.

  • Peptide Quantitation

    The determination of signature peptide concentration from biological matrices using LC-MS. Scientists utilize peptide quantitation to deconvolute complex chromatograms by searching for specific peptide sequences, which can analyze the peptides with high sensitivity and specificity, even at low levels of peptide.

  • Charge Variant Analysis (IEX)

    Separate MABs from from acidic/basic variants .

  • Whether you are working with
  • novel proteins

    Complex large molecules composed of amino acid polymer chains. Proteins in biopharmaceuticals typically range from 3,000-150,000 kDa. Under the biologics classification, biopharmaceutical proteins can be hormones, human growth factors, and monoclonal antibodies (mAbs). The most common biopharmaceutical proteins are insulin and mAbs.

  • or biosimilars

    A biologic with the same sequence and similar function to an innovator biologic. The characterization of biosimilars requires the same chromatographic techniques as its corresponding innovator biologic

  • Biozen UHPLC columns are guaranteed
  • to help you analyze large biologics. Explore bioZen Nano LC Columns: Focus, Fractionate, and Trap!
biozen nano LC columns

Biozen 0.075mm ID columns allow for minimized band broadening and improved analyte focusing for increased sensitivity for separation of omics. biozen 0.075mm ID columns are available in the following phases and particle sizes:

  • 3µm PS-C18
  • 3µm Polar C18
  • 2.6µm XB-C18

Introducing Biozen NX-C18 phase for robust, reproducible, high pH fractionation. bioZen NX-C18 columns offre high efficiency and reproducible performance in comparsion to traditional fractionation columns on the market

biozen LC columns
biozen nano LC traps

Biozen trap columns are the perfect fit for your 0.075mm ID nano LC columns and are available in both a general reverse phase and aqueous stable reversed phase selectivities.

dSEC-2


dSEC-2 Phase Information


Biozen Size Exclusion Chromatography Columns

Advanced SEC Silica Particle Technology and Surface Chemistry for Characterizing Biomolecules

  • Exceptionally Robust SEC Particle
  • Extreme Stability and Exceptional Lifetime
  • Reproducible Separations

Biozen SEC Proprietary Silica Particle Technology

The Biozen dSEC columns are packed with low pore volume silica coupled with a proprietary hydrophilic diol-type bonded surface chemistry that prevents the silica surface from interacting with protein samples.

bioZen dSEC technology

Improved mechanical strength with silica to improve column packing. Column stability exceeding 100 hours even with harsh MP and high flow-rates

Part Number Particle Size (µm) Length (m) Internal Diameter (mm)  
00F-4788-E0 3 µm 150 4.6 Buy Now
00H-4788-E0 3 µm 300 4.6 Buy Now
00F-4788-K0 3 µm 150 7.8 Buy Now
00H-4788-K0 3 µm 300 7.8 Buy Now
00B-4787-AN 1.8 µm 50 2.1 Buy Now
00F-4787-AN 1.8 µm 150 2.1 Buy Now
00F-4787-E0 1.8 µm 150 4.6 Buy Now
00H-4787-E0 1.8 µm 300 4.6 Buy Now

Biozen SEC Hydrophilic Surface Chemistry Improves Aggregate Analysis

bioZen dSEC Aggregate Recovery Chart

Improved Column Lifetime and Performance Stability

Phenomenex’s optimized SEC column loading technology has significantly improved the overall packing density and silica distribution of the columns leading to improved chromatographic lifetime and stability.

Unchanged Performance After 300 Injections

bioZen dSEC 300 Injections Chart

Unchanged Performance After 100 Hours of Extreme Running Conditions

bioZen dSEC Column Comparison

New Standard for Platform SEC Methods

Whether IgG2 or IgG4 isotypes, bispecifics, or Fc-Fusions, dSEC-2 provides excellent separation and sample recovery for many different classes of antibodies and related recombinant proteins.

bioZen dSEC Trastuzumab Chart
Conditions for both separations:
Column:
Biozen 1.8 μm dSEC-2, 200 Å
Dimension:
300 x 4.6 mm
Part No.:
00H-4787-E0
Mobile Phase:
200 Potassium Phosphate +
250 mM KCl, pH 6.2
Flow Rate:
0.35 mL/min
Injection Volume:
10 μL
Temperature:
25 ˚C
Detection:
UV @ 280 nm
Sample:
As noted

Featured

Phase: Particle Size: Pore Size: Length: Internal Diameter:
Loading...

Part Number:00H-4787-E0

Description:Biozen™ 1.8 µm dSEC-2, 200 Å, LC Column 300 x 4.6 mm, Ea

Required Holder:

Stationary Phase:

Solid Support:

Format:Column

Separation Mode:

Recommended Use:

USP Designation:


 Search Results


Part
Number
Brand Phase Particle
Size (µm)
Pore
Size (Å)
Length (mm) Internal
Diameter (mm)
Price